Swiss pharmaceutical company, Dipharma, has successfully developed a new fast dissolving formulation of carglumic acid tablets that are stable at room temperature.
Soluble tablets
Carglumic acid is used in the management of rare, life-threatening inborn metabolic disorders affecting the urea cycle. It will strengthen the company’s portfolio of improved formulations for the treatment of patients suffering from inborn errors of metabolism.
“This achievement is another milestone in the expansion of our pipeline, aimed at improving the life of patients suffering from inborn errors of metabolism,” said Marc-Olivier Geinoz, CEO of Dipharma. “We worked hard to develop an improved formulation meeting patients’ requirements: today our R&D efforts were rewarded with the confirmation that our new formulation is fast dissolving and stable at room temperature.”
Additionally, the company has announced the filing of a patent application for the fast dissolving and stable tablet formulations of carglumic acid, together with the proprietary technology developed to improve the product stability, without modifying the pharmaceutical form the patients are familiar to.